AlphaCore Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

AlphaCore Capital’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$279K	Buy	+19,488	New	+$254K	﹤0.01%	1132

Other funds holding FDMT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

AlphaCore Capital's FDMT Position: Q3 2026 in Review

AlphaCore Capital opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 19,488 shares worth $279K. The stake represents ﹤0.01% of the portfolio and ranks #1132 among its holdings.

53 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

AlphaCore Capital held 19,488 shares of 4D Molecular Therapeutics worth $279K as of Q3 2026.
4D Molecular Therapeutics was a new AlphaCore Capital position in Q3 2026.
4D Molecular Therapeutics made up ﹤0.01% of AlphaCore Capital's portfolio in Q3 2026, its #1132 holding.
53 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.